Poster Session 1 | Tumor Immunology

 

P01.01. - P01.03 Withdrawn

​

P01.04. Sensitivity of different cell lines to NK cell lysis

Vladimir Jurisic, Kragujevac, Serbia

 

P01.05. IOMX-0675, a LILRB1/LILRB2 cross-specific antibody that reprograms the tumor microenvironment to trigger potent anti-tumor activity

Stefan Bissinger, Martinsried, Germany

 

P01.06. ICMT inhibition as a targeted approach for increasing MHC-I expression and blocking immune evasion in ovarian cancer

Ruiqian Zhang, Hong Kong, Hong Kong

 

P01.07. The Role of PP2Ac in Regulating Immune Evasion in High Grade Serous Ovarian Cancer

Xin HE, Hong Kong, Hong Kong

 

P01.08. PVR-CD226 interaction regulates IL-10 production during human T cell differentiation

Ester Lozano, Barcelona, Spain

 

P01.09. Fas-L mediated death of activated intratumoral T cells drives secondary resistance to Treg depletion in cancer

Chen Qing, London, United Kingdom

 

P01.10. Promoter methylation facilitates escape from specific immune responses against tumor-associated antigens across cancer types and can be overcome by demethylating agents

Martin Thelen, Cologne, Germany

 

P01.11. Withdrawn

 

P01.12. Impact of glutamate metabolism and its inhibition on melanoma development and immune cells

Patrizia Stoitzner, Innsbruck, Austria

 

P01.13. SECN-15: An antisense oligonucleotide-based approach to target expression of Neuropilin-1 induces anti-tumor activity in vivo and boosts efficacy of checkpoint inhibitors

Andre Maaske, Planegg, Germany

 

P01.14. Intracellular and extracellular biochemical functions of V-domain Ig-containing suppressor of T cell activation are regulated by crucial factors of tumour microenvironment

Vadim Sumbayev, Chatham Maritime, United Kingdom

 

P01.15. Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models

Lisa Gregor, Munich, Germany

 

P01.16. GDF-15 inhibition overcomes treatment resistance to platinum-based chemoimmunotherapy

Neha Vashist, Planegg-Martinsried, Germany

 

P01.17. Characterization of Neutrophil Subpopulations in Pancreatic Cancer Through a High-Dimensional Surface Marker Screen

Nilofer Abdul Razak, Gräfelfing, Germany

 

P01.18. Withdrawn

​

​​

Poster Session 2 | Mode of action of Immune Therapies

​

P02.01. Developing new and effective strategies for adoptive T- cell therapy in pediatric gliomas

Or Zohar, Tel Aviv, Israel

 

P02.02. The Influence of Fecal Supernatants from Melanoma Patients on CAR T Cell Cytotoxicity and Immune Modulation

Ying Wang, München, Germany

 

P02.03. Artificial targets for functional characterization of CAR T cells

 Borgelt, Bergisch Gladbach, Germany

 

P02.04. Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response

Omar Abdelmotaleb, Schlieren, Switzerland

 

P02.05. GDF-15 neutralization enhances T cell infiltration in solid tumor models

Arman Oner, Munich, Germany

 

P02.06. Chimeric VSV-NDV mediates a multifaceted immune response in solid cancers which is enhanced by expression of high-affinity soluble PD-1

Jennifer Altomonte, Munich, Germany

 

P02.07. The combination of a STING agonist and IL15 efficiently reverses the immunosuppressive tumor microenvironment in a complex primary human organoid model

Daphni Ammon, Vienna, Austria

 

​

Poster Session 3 | New Targets and New Leads

​

P03.01. Generation and characterization of recombinant Vpx coupled to cell penetrating peptides

Selin Aidin, Munich, Germany

 

P03.02. The prognostic role of glycodelin through the interaction with the tumor microenvironment in NSCLC

Lisa Strotmann, Heidelberg, Germany

 

P03.03. Granulopoiesis and thrombopoiesis aberrantly synergize in cancer to promote tumor progression

Bojan Smiljanov, Munich, Germany

 

P03.04. Targeting CXCR4: Implications for Clonal Dynamics and MRD Assessment in Acute Myeloid Leukemia

Enise Ceran, Heidelberg, Germany

 

P03.05. scFv-dependent anti-tumor efficacy of CAR-T cells targeting novel antigens in Acute Myeloid Leukemia

Shifaa Abdin, Heidelberg, Germany

 

P03.06. EGFL7, an angiogenic factor, induces immunosuppression in malignant glioma

Sukrit Mahajan, Dresden, Germany

​

P03.07. Bringing your conventional flow cytometer to the spectral dimension: 88-channel detection system in a CytoFLEX LX Flow Cytometer 

Kelly Andrews, Qianjun Zhang*, Omayra Mendez-Solis, Milan Popovic, Marcus Zhao, Ellison Han, Josen Ren, Leon Huang, James Tung, Anis Larbi§, Development, Beckman Coulter Life Sciences, Miami, FL 33196; *Field Application, Beckman Coulter Life Sciences, San Jose, CA, 95134; §Global Medical and Scientific Affairs, Beckman Coulter Life Sciences

 

 

Poster Session 4 | Polyspecific Antibody Derivatives

​

P04.01. CSF1R-targeting T cell engaging bispecific antibodies for Acute Myeloid Leukemia treatment

Thomas Janert, München, Germany

​

​

​Poster Session 6 | Cancer Vaccines

​

P06.01. Survivin-based vaccine induces durable tumor regression when integrated with specific sequential antiangiogenic and immune checkpoint therapies

Fanny Méjean, Paris, France

 

P06.02. Enhancing Cancer Immunotherapy through Synthetic Biology: A Novel Heterologous Prime-Boost Strategy

Ilaria Esposito, Roma, Italy

 

​

 

Poster Session 7 | Young Researcher Session

​

P07.01. Modular targeting of acute myeloid leukemia with anti-P329G adapter CAR T cells

Sophia Stock, Munich, Germany

 

P07.02. Pembrolizumab associated to chemotherapy in solid tumor:A retrospective study about 11 cases

Meryem Boudjerda, Constantine, Algeria

 

P07.03. A20 as a novel immune checkpoint in KRAS-driven lung adenocarcinoma

Monika Homolya, Vienna, Austria

 

P07.04. Mantle Cell Lymphoma in sight: development of anti-ROR1 CAR T-cell therapy, andenhancement of its safety profile by iCasp9 suicidal gene expression

Madalina Nistor, Cluj-Napoca, Romania

 

P07.05. Overcoming endothelial cell anergy by VEGFR2 inhibition to enhance CAR T cell response in aggressive B cell lymphoma

Lilli Schlözer, Cologne, Germany

 

​

 

Poster Session 8 | Cellular Therapies (including combinations)

​

P08.01. A combinatorial therapy for bladder cancer: epigenetic inhibitor and CAR-NK cells

Lucia Morales, Madrid, Spain

 

P08.02. Adoptive cell therapy with Cytokine-Induced Killer cells armed with immunotools against HER-2 expressing breast cancer.

Ngo Hieu, Padova, Italy

 

P08.03. Eliminating operator errors in Flow analytics: dried reagents and fully automated flow gating provide fast and robust CAR T cell analytics

Cesar Evaristo, Bergisch Gladbach, Germany

 

P08.04. Impact of variability of CD4+/CD8+ T cell ratios on the functional properties of CAR T cell products

Cesar Evaristo, Bergisch Gladbach, Germany

 

P08.05. Dried antibody cocktails are setting the benchmark for fast and robust CAR T cell flow cytometric analysis

Borgelt, Bergisch Gladbach, Germany

 

P08.06. Optimizing promoter systems to enhance cytokine response in CAR T cells for tumor therapy

Lisa Steger, Erlangen, Germany

 

P08.07. Evaluation of CAR T cell function in advanced 3D heterospheroid models reveals monocyte-dependent protection against cancer cell killing

Natasha Madsen, Hørsholm, Denmark

 

P08.08. Withdrawn

​​

P08.09. Robust ex-vivo expansion of tumour-infiltrating lymphocytes from ovarian cancer biopsies using dendritic cells derived from the leukemic cell line DCOne

Satwinder Kaur Singh, Stockholm, Sweden